IP Library Granted Patent US 9,012,436
Granted Patent B2
US 9,012,436 · App. 12/989,948 · Granted Apr 21, 2015

Lipid composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,436
App. No.
12/989,948
Granted
Apr 21, 2015
Kind
B2
Abstract

We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm.

Claims (17)

1. A pharmaceutical composition adapted for oral delivery of an effective amount of an effective amount of native testosterone consisting of:

2.5-7.5% w/w native testosterone;

at least 40% w/w sesame oil;

at least 30% w/w lauroglycol;

at least 5% w/w ethanol;

at least 15% w/w benzyl alcohol; and

a pharmaceutically acceptable carrier wherein the combination of ethanol and benzyl alcohol increases the solubility and bioavailability of native testosterone when administered to a subject.

2. The composition according to claim 1 wherein the effective amount of native testosterone is 40 mg.

3. The composition according to claim 1 wherein the effective amount of native testosterone is 20 mg.

4. A method to treat male hypogonadism, comprising:

administering an effective amount of the composition of claim 1 to a male subject having hypogonadism, wherein the composition is administered in accordance with the circadian secretion of testosterone to provide physiological replacement of testosterone, thereby treating the male hypogonadism.

5. The method according to claim 4 , wherein the composition is administered prior to sleep between 20:00 hours and 24:00 hours.

6. The composition according to claim 1 , consisting of 5.46% w/w native testosterone, 5.3% w/w ethanol, 15.93% w/w benzyl alcohol, 31.80% w/w lauroglycol and 41.51% w/w sesame oil.

7. The composition according to claim 1 , consisting of 2.73% w/w native testosterone, 5.46% w/w ethanol, 16.39% w/w benzyl alcohol, 32.72% w/w lauroglycol and 42.7% w/w sesame oil.

8. The composition according to claim 1 wherein said composition is contained in a capsule.

9. The method according to claim 4 , wherein the male hypogonadism is primary male hypogonadism.

10. The method according to claim 4 , wherein the male hypogonadism is secondary male hypogonadism.

Assignments (2)
CHANGE OF NAME Recorded Oct 20, 2025
From: DIURNAL LIMITED
To: NEUROCRINE UK LIMITED
Reel/Frame 072609/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2010
From: HUATAN, HIEP; ROSS, RICHARD
To: DIURNAL LIMITED
Reel/Frame 025221/0083 →